SBIR/STTR Research Award
GROWTH ACTIVATING FACTOR FOR MYCOBACTERIUM TUBERCULOSIS
Award amount
$218,482Program and phase
SBIR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- MYCOS RESEARCH, LLC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): In this proposal we are requesting funding
for proof of principle research into Mycobacterial Growth Activating Factors
(GAFs). The long-term objective of these studies is the production of a
commercial product that would significantly reduce the time required for
diagnosis and drug susceptibility screening of tuberculosis. The aims of this
proposal are to: (1) establish the growth promoting characteristics of GAFs
using both clinical and laboratory isolates of M tuberculosis. (2) Evaluate the
potential use of GAFs in drug susceptibility testing. (3) Determine the effects
of GAFs in a clinical setting. And (4) Evaluate derivatives of our defined
peptides for potential activity and test for synergistic combinations. If
successful, these products could lead to multiple innovative uses that range
from the improvement of diagnoses in developing nations to significantly faster
identification of efficacious therapeutic drug regimens.
PROPOSED COMMERCIAL APPLICATION:
MycoQuick Growth Media: A culture medium supplement that reduces the time required for the
culture of slow growing mycobacteria species. This in turn will significantly reduce the lengthy
time required for laboratory diagnosis of infection with M. tuberculosis. Rapid diagnosis will also
permit the timely initiation of drug therapy in these patients and permit rapid drug resistance
profiling.
MycoQuice Diagnostic Kit: A diagnostic kit for M- tuberculosis, specifically targeted for use
under laboratory conditions commonly encountered in developing nations. This product will
incorporate the MycoQuick growth medium in pre-prepared assemblies with or without drugs
commonly prescribed and anti-tuberculosis therapy. MycoQuick Kit will facilitate both rapid
diagnosis and drug susceptibility profiling in a format conducive for use under the less
stringent conditions found in distant third world sites. This product may have a significant
impact in these regions where tuberculosis is endemic.
Technology keywords
Not reported